187 related articles for article (PubMed ID: 12824197)
21. Infectious complications of biologic agents.
Martin-Mola E; Balsa A
Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
[TBL] [Abstract][Full Text] [Related]
22. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Okada SK; Siegel JN
JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
[No Abstract] [Full Text] [Related]
23. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Emery P; Keystone EC; Schiff MH; van Riel PL; Weinblatt ME; Weisman MH
Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii2-15. PubMed ID: 17038465
[No Abstract] [Full Text] [Related]
24. [Modern therapy of rheumatoid arthritis. Joint destruction can be delayed].
Neumaier J
MMW Fortschr Med; 2008 Apr; 150(14):14. PubMed ID: 18488571
[No Abstract] [Full Text] [Related]
25. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
Mizutani W
Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
[TBL] [Abstract][Full Text] [Related]
26. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.
Boulton JG; Bourne JT
Rheumatology (Oxford); 2007 Jan; 46(1):178-9. PubMed ID: 16998233
[No Abstract] [Full Text] [Related]
27. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
Hernández MV; Sanmartí R; Cañete JD
Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029
[TBL] [Abstract][Full Text] [Related]
28. Advances in targeted therapy: safety of biological agents.
Keystone EC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii34-6. PubMed ID: 14532146
[No Abstract] [Full Text] [Related]
29. Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.
van den Hout WB
Nat Clin Pract Rheumatol; 2009 Feb; 5(2):78-9. PubMed ID: 19107111
[No Abstract] [Full Text] [Related]
30. Etanercept: anti-tumor necrosis factor therapy for rheumatoid arthritis.
McGahan L
Issues Emerg Health Technol; 1999 Oct; (8):1-6. PubMed ID: 11811215
[No Abstract] [Full Text] [Related]
31. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
Kavanaugh A; Cohen S; Cush JJ
J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
[No Abstract] [Full Text] [Related]
32. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
Kulp W; Greiner W; Graf von der Schulenburg JM
Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
[No Abstract] [Full Text] [Related]
33. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
Kavanaugh A
Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
[No Abstract] [Full Text] [Related]
34. Biologics in rheumatoid arthritis.
Sharma PK; Hota D; Pandhi P
J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
[TBL] [Abstract][Full Text] [Related]
35. Malignancy and biologic therapy in rheumatoid arthritis.
Askling J; Bongartz T
Curr Opin Rheumatol; 2008 May; 20(3):334-9. PubMed ID: 18388527
[TBL] [Abstract][Full Text] [Related]
36. [Tumor necrosis factor modulators in the treatment of rheumatoid arthritis].
Konttinen YT; Valleala H; Honkanen V; Törnwall J; Tensing EK; Sorsa T; Nordström D
Duodecim; 1999; 115(18):1969-76. PubMed ID: 11941814
[No Abstract] [Full Text] [Related]
37. Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening.
Rahman N; Healy C; Flint SR; Stassen LF
J Clin Rheumatol; 2010 Jun; 16(4):197-9. PubMed ID: 20511984
[No Abstract] [Full Text] [Related]
38. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
Hyrich KL; Silman AJ
J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
[No Abstract] [Full Text] [Related]
39. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.
Franklin JP; Symmons DP; Silman AJ
Ann Rheum Dis; 2005 May; 64(5):657-8. PubMed ID: 15834052
[No Abstract] [Full Text] [Related]
40. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
